基于数据挖掘和网络药理学探讨谢旭善教授治疗乙肝肝硬化湿热内蕴证的配伍规律与作用机制OA
Medication compatibility rules of Professor XIE Xushan in treating hepatitis B cirrhosis of the internal damp-heat syndrome and action mechanism based on data mining and network pharmacology
目的:通过数据挖掘分析谢旭善教授治疗乙肝肝硬化(乙型病毒性肝炎导致的肝硬化)湿热内蕴证方剂的用药配伍规律,并运用网络药理学及分子对接技术分析药物的作用靶点及机制.方法:收集汇总谢旭善教授治疗乙肝肝硬化的首诊处方并录入中医传承辅助平台进行统计分析.通过中药系统药理学数据库与分析平台(TCMSP)筛选新处方的活性化合物并预测其作用靶点,以"HBV-hepatic cirrhosis(乙肝肝硬化)"为关键词在基因名片数据库(GeneCards)、在线人类孟德尔遗传数据库(OMIM)、药物数据库(DrugBank)搜索乙肝肝硬化疾病相关靶点,并与新组方化合物作用靶点取交集,通过生物分子功能注释系统数据库(STRING)构建蛋白质-蛋白质相互作用网络图,用 CytoNCA 网络拓扑分析筛选核心基因,后续导入 Cytoscape 进行美化,将关键靶点导入 R 软件进行富集分析,并使用 AutoDock 程序及 PyMOL 进行分子对接.结果:本研究共纳入患者 151例,录入 151 首方剂,得到高频药物 12 种、核心药对前 20 组、1 首新组方,获得新组方中药有效成分化合物 134 个、相关作用靶点 1 103 个,乙肝肝硬化疾病相关靶点 2 150 个,药物-疾病共同靶点 109 个,经 STRING 平台和 Cytoscape 3.10.2 拓扑分析得到 6 个核心靶标.通过基因本体论(GO)功能富集分析获得 108 个相关条目,通过京都基因与基因组百科全书(KEGG)通路富集分析获得 103 条信号通路,主要活性成分有槲皮素、芹菜素、汉黄芩素、β-谷甾醇、黄芩苷、大黄素等,作用于白细胞介素-6(interleukin-6,IL-6)、丝氨酸/苏氨酸蛋白激酶 1(Akt serine-threonine protein kinase 1,AKT1)、丝裂原活化蛋白激酶 1(mitogen-activated protein kinase 1,MAPK1)、C 反应蛋白(C-reactive protein,CRP)、雌激素受体 1(estrogen receptor 1,ESR1)、纤连蛋白 1(fibronectin 1,FN1)等靶点,通过磷脂酰肌醇 3 激酶(phosphatidylinositol 3-kinase,PI3K)-蛋白激酶B(Akt)信号通路、晚期糖基化终末产物(advanced glycation end product,AGE)-晚期糖基化终末产物受体(advanced glycation end product receptor,RAGE)信号通路、乙型病毒性肝炎等关键信号通路干预乙肝肝硬化.分子对接结果显示,主要活性成分与核心靶点有强烈的结合活性.结论:通过数据挖掘、网络药理学分析和分子对接技术,得出谢旭善教授治疗乙肝肝硬化湿热内蕴证配伍规律及作用机制,可为乙肝肝硬化的临床治疗提供思路.
Objective:To analyze the medication compatibility rules of Professor XIE Xushan's prescriptions for the treatment of hepatitis B cirrhosis with internal damp-heat syndrome through data mining,and to analyze the target and action mechanism of its drugs by using network pharmacology and molecular docking.Methods:The initial visit prescriptions of Prof.XIE Xushan for the treatment of hepatitis B cirrhosis were collected and summarized and entered into the Traditional Chinese Medicine Inheritance Support System for statistical analysis.The active compounds of the new formula were screened and their potential targets were predicted via the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP).Then,disease-related targets of hepatitis B cirrhosis were retrieved from the GeneCards Database,Online Mendelian Inheritance in Man(OMIM)and DrugBank Database using the keyword HBV-hepatic cirrhosis.The intersection of the compound targets of the new formula and the disease-related targets was obtained,and a protein-protein interaction(PPI)network diagram was constructed with the help of the Search Tool for the Retrieval of Interacting Genes/Proteins database(STRING).Network topology analysis was performed and core genes were screened via CytoNCA,followed by visualization optimization in Cytoscape.Key targets were imported into R software for enrichment analysis,and molecular docking was conducted using AutoDock and PyMOL.Results:A total of 151 patients were enrolled in this study,with 151 prescriptions collected.From the analysis,12 high-frequency medicines,the top 20 core couplet medicinals,and 1 new formula were identified.The new formula yielded 134 active components of traditional Chinese medicines and 1 103 related action targets.A total of 2 150 disease-related targets were screened for hepatitis B cirrhosis,and 109 common targets were obtained through intersection analysis.Six core targets were identified via topological analysis using degree values by the STRING platform and Cytoscape 3.10.2.A total of 108 entries were obtained from GO functional enrichment analysis and 103 pathways from KEGG enrichment analysis.The main active components included quercetin,apigenin,wogonin,etc.,which acted on targets such as IL-6,AKT1,MAPK1,CRP,ESR1.These components intervened in the treatment of hepatitis B cirrhosis through key signaling pathways including the PI3K-Akt signaling pathway,AGE-RAGE signaling pathway and the hepatitis B pathway.Molecular docking results showed that the main active components had strong binding affinity with the core targets.Conclusion:Through data mining,network pharmacology analysis and molecular docking,the compatibility rules and action mechanism of Professor XIE Xushan's treatment for hepatitis B cirrhosis of the internal damp-heat type were clarified,which may offer novel insights into the clinical treatment of hepatitis B cirrhosis.
王丰羽;张向磊;张晓华;曲卫;王琳
山东中医药大学第一临床医学院,山东 济南,250014青岛市中医医院/青岛大学附属青岛市海慈医院,山东 青岛,266033青岛市中医医院/青岛大学附属青岛市海慈医院,山东 青岛,266033青岛市中医医院/青岛大学附属青岛市海慈医院,山东 青岛,266033青岛市中医医院/青岛大学附属青岛市海慈医院,山东 青岛,266033
医药卫生
乙肝肝硬化湿热内蕴证分子对接作用靶点
Hepatitis B cirrhosisInternal damp-heat syndromeMolecular dockingTarget of action
《中医临床研究》 2026 (19)
22-32,11
全国名老中医药专家传承工作室建设项目(国中医药人教函[2022]75号)基于网络药理学和分子对接技术探讨谢旭善教授治疗乙肝肝硬化用药物配伍规律及作用机制的研究(M-2023243)基于网络药理学和分子对接技术探讨护肠清毒微丸治疗慢性肝衰竭大鼠肠源性内毒素血症机制的研究(2022-WJZD044).
评论